Domain Therapeutics is a biopharmaceutical startup that is focused on developing innovative cancer treatments. The company's primary area of research is GPCR (G protein-coupled receptors) mediated-immunosuppression. In simpler terms, they are working on drugs that can help the immune system fight against tumors more effectively.

The company's pipeline includes a variety of potential treatments, some of which are in Phase I of clinical trials. These include an A2aR/A2bR antagonist (M1069) and an EP4 receptor antagonist (DT-9081). They also have a couple of candidates in the discovery phase, including an anti-CCR8 antibody (DT-7012) and a PAR2 antagonist (DT-9045).

Domain Therapeutics operates in the biotech market, specifically in the oncology sector. Their business model revolves around the research, development, and eventual commercialization of their cancer treatments. They make money by progressing their treatments through the various phases of clinical trials, with the aim of eventually selling these treatments to healthcare providers and patients.

The company serves a broad range of clients, including healthcare providers, patients, and other stakeholders in the healthcare industry. They are committed to advancing multiple first-in-class and best-in-class programs to tackle GPCR-mediated immunosuppression in immune-oncology.

Keywords: Biopharmaceutical, Cancer Treatments, GPCR Mediated-Immunosuppression, Clinical Trials, Oncology, A2aR/A2bR Antagonist, EP4 Receptor Antagonist, Anti-CCR8 Antibody, PAR2 Antagonist, Immune-Oncology.